Report Overview

The global Renal Cancer drugs market size stood at USD 3.6 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, making up 90-95% of all kidney cancer cases. Globally, RCC represents the sixth most frequently diagnosed cancer in men and 10th in women. RCC consists of a heterogeneous group of tumors with distinct genetic and metabolic defects.A total of 7 new entrants are expected to launch over the forecast period in the 8MM from 2019-2028 while specific marketed agents are expected to undergo label expansion. The competition will be particularly fierce in renal cell carcinoma, immune checkpoint inhibitors and combinations thereof competing for market share in the adjuvant setting and in first-line treatment of metastatic RCC. The renal cell carcinoma market is expected to develop at a decent rate due to the increased incidence reported worldwide.



Market Drivers

Drivers of the renal cell carcinoma market include changing lifestyles, increased levels of smoking & tobacco consumption, misuse of certain painkillers, obesity, and the growing geriatric population. The promotion of novel and innovative diagnostics and therapeutic procedures such as cytokine and nephrectomy boost the growth opportunities for key market players in this market, promoting growth during the forecast period across the world. The increasing prevalence of the geriatric population and growing demand for extensive diagnostics tests leads to the development and adoption of novel therapy procedures, which is creating several growth opportunities or the stakeholders operating in the global kidney cancer diagnostics therapeutics market. An increasing number of research and development activities for kidney cancer diagnostics and the emergence of technically advanced tests are likely to expand growth opportunities for the key players functioning in the international marketplace.